首例RNA干扰药物问世及该领域技术演化历程

近期,RNA干扰(RNAi)制药公司Alnylam开发的小干扰RNA (siRNA)药物ONPATTRO?美国食品与药物管理局和欧盟委员会批准上市,用于治疗成人患者的遗传性转甲状腺素蛋白淀粉样变性引起的多发性神经病变.这是全球第一款RNAi药物,该事件标志着人类继小分子化合物、单克隆抗体蛋白类药物后,在前沿生物制药领域实现了新的突破,意味着RNAi疗法从基础研究到临床治疗的开发全过程首次贯通,具有里程碑式的意义.本文概述了该药物及适应症的基本情况,介绍了RNAi发现历史、作用机理与药物特征,RNAi药物的研发历程,以及该领域关键技术的最新研究进展.     

Clinical advances of siRNA therapeutics

Small interfering RNA (siRNA) enables efficient target gene silencing by employing a RNA interference (RNAi) mechanism, which can compromise gene expression and regulate gene activity by cleaving mRNA or repressing its translation. Twenty years after the discovery of RNAi in 1998, ONPATTRO? (patisiran) (Alnylam Pharmaceuticals, Inc.), a lipid formulated siRNA modality, was approved for the first time by United States Food and Drug Administration and the European Commission in 2018. With this milestone achievement, siRNA therapeutics will soar in the coming years. Here, we review the discovery and the mechanisms of RNAi, briefly describe the delivery technologies of siRNA, and summarize recent clinical advances of siRNA therapeutics.     

Selection and optimization of asymmetric siRNA targeting the human c-MET gene

The silencing of specific oncogenes via RNA interference (RNAi) holds great promise for the future of cancer therapy. RNAi is commonly carried out using small interfering RNA (siRNA) composed of a 19 bp duplex region with a 2-nucleotide overhang at each 3′ end. This classical siRNA structure, however, can trigger non-specific effects, which has hampered the development of specific and safe RNAi therapeutics. Previously, we developed a novel siRNA structure, called asymmetric shorter-duplex siRNA (asiRNA), which did not cause the non-specific effects triggered by conventional siRNA, such as off-target gene silencing mediated by the sense strand. In this study, we first screened potent asiRNA molecules targeting the human c-MET gene, a promising anticancer target. Next, the activity of a selected asiRNA was further optimized by introducing a locked nucleic acid (LNA) to maximize the gene silencing potency. The optimized asiRNA targeted to c-MET may have potential as a specific and safe anticancer RNAi therapeutic.     

Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo

Within the recent years, RNA interference (RNAi) has become an almost-standard method for in vitro knockdown of any target gene of interest. Now, one major focus is to further explore its potential in vivo, including the development of novel therapeutic strategies. From the mechanism, it becomes clear that small interfering RNAs (siRNAs) play a pivotal role in triggering RNAi. Thus, the efficient delivery of target gene-specific siRNAs is one major challenge in the establishment of therapeutic RNAi. Numerous studies, based on different modes of administration and various siRNA formulations and/or modifications, have already accumulated promising results. This applies to various animal models covering viral infections, cancer and multiple other diseases. Continuing efforts will lead to the development of efficient and “double-specific” drugs, comprising of siRNAs with high target gene specificity and of nanoparticles enhancing siRNA delivery and target organ specificity.     

小干扰RNA靶向VEGF基因体内外抑制乳腺癌细胞MCF-7的增殖

 血管生成与肿瘤生长、侵袭、转移密切相关.血管内皮生长因子能特异地促进内皮细胞分裂、增殖及迁移,在肿瘤新生血管生成过程中起着至关重要的作用.通过RNAi抑制VEGF表达的抗血管生成疗法可有效应用于肿瘤治疗.本研究采用化学修饰的siRNA在体内外抑制VEGF基因表达,探讨化学修饰的siRNA介导的RNA干扰技术在乳腺癌基因治疗的可行性和特异性.选用阳离子脂质体Lipofectamine^TM2000作为转染试剂,将针对人VEGF基因的小干扰RNA(small interfering RNA,siRNA)转染人类乳腺细胞株MCF-7和裸鼠移植瘤,在体内外诱导RNAi.采用四甲基偶氮唑蓝（MTT）法,逆转录聚合酶链反应(RT-PCR),蛋白印迹实验等检测siRNA治疗组和对照组VEGF基因表达及细胞增殖变化.体外实验结果显示：靶向VEGF基因siRNA转染乳腺癌MCF-7细胞后,细胞生长抑制率达52.5%;VEGF的mRNA和蛋白表达水平显著降低（P<0.01）;裸鼠体内实验结果显示：siRNA治疗组瘤组织的增长受到明显抑制;RT-PCR结果同时表明治疗组VEGF表达下调.体内外对照组各指标无显著变化.化学修饰的siRNA介导的RNAi在体内外均能成功下调靶基因VEGF的表达,抑制MCF-7细胞增殖,是潜在的肿瘤治疗新方法.     

siRNA的体内递送

siRNA是一种由siRNA介导的转录后基因沉默。自利用RNAi沉默目的基因获得成功以来, 体内应用RNAi的研究受到高度重视。由于siRNA本身的不稳定性以及体内的复杂环境, siRNA递送的安全性与有效性成为目前关注的重点。文章就目前报道的siRNA体内递送方式进行了综述。     

综述: siRNA脂质纳米输送载体的研究进展

siRNA能高效且特异地阻断内源性同源基因的表达即RNA干涉(RNAi)．RNAi在临床中的应用需要开发安全有效的输送系统,脂质纳米输送载体是一种具有发展潜力的siRNA输送系统．siRNA-脂质复合物的形成主要通过静电相互作用,静电作用必须足够强以至于载体在运输过程中不释放siRNA,而载体到达治疗部位时,解聚释放出siRNA．载体的粒径应小于100 nm,以利于细胞的摄取和透过特定部位的血管开窗．为了减少网状内皮系统(RES)的摄取和延长载体的循环时间,载体的表面由聚乙二醇修饰．本文主要综述了构建siRNA输送载体的基本要求．     

RNAi and microRNA: breakthrough technologies for the improvement of plant nutritional value and metabolic engineering

This article raises the complex issue of improving plant nutritional value through metabolic engineering and the potential of using RNAi and micro RNA technologies to overcome this complexity, focusing on a few key examples. It also highlights current knowledge of RNAi and microRNA functions and discusses recent progress in the development of new RNAi vectors and their applications. RNA interference (RNAi) and microRNA (miRNA) are recent breakthrough discoveries in the life sciences recognized by the 2006 Nobel Prize in Physiology or Medicine. The importance of these discoveries relates not only to elucidating the fundamental regulatory aspects of gene expression, but also to the tremendous potential of their applications in plants and animals. Here, we review recent applications of RNAi and microRNA for improving the nutritional value of plants, discuss applications of metabolomics technologies in genetic engineering, and provide an update on the related RNAi and microRNA technologies.     

The therapeutic potential of RNA interference

In recent years, we have witnessed the discovery of a new mechanism of gene regulation called RNA interference (RNAi), which has revitalized interest in the development of nucleic acid-based technologies for therapeutic gene suppression. This review focuses on the potential therapeutic use of RNAi, discussing the theoretical advantages of RNAi-based therapeutics over previous technologies as well as the challenges involved in developing RNAi for clinical use. Also reviewed, are the in vivo proof-of principle experiments that provide the preclinical justification for the continued development of RNAi-based therapeutics.     

Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia

Leukaemia is a bone marrow cancer occurring in acute and chronic subtypes. Acute leukaemia is a rapidly fatal cancer potentially causing death within a few weeks, if untreated. Leukaemia arises as a result of disruption to haematopoietic precursors, caused either by acquired gene fusions, gene mutations or inappropriate expression of the relevant oncogenes. Current treatment options have made significant progress, but the 5 year survival for acute leukaemia remains under 10% in elderly patients, and less than 50% for some types of acute leukaemia in younger adults. For chronic leukaemias longer survival is generally expected and for chronic myeloid leukaemia patients on tyrosine kinase inhibitors the median survival is not yet reached and is expected to exceed 10 years. Chemotherapy and haematopoietic stem cell transplantation (HSCT) for acute leukaemia provide the mainstay of therapy for patients under 65 and both carry significant morbidity and mortality. Alternative and superior therapeutic strategies for acute leukaemias are urgently required. Recent molecular-based knowledge of recurring chromosome rearrangements, in particular translocations and inversions, has resulted in significant advances in understanding the molecular pathogenesis of leukaemia. Identification of a number of unique fusion genes has facilitated the development of highly specific small interfering RNAs (siRNA). Although delivery of siRNA using multifunctional nanoparticles has been investigated to treat solid cancers, the application of this approach to blood cancers is at an early stage. This review describes current treatments for leukaemia and highlights the potential of leukaemic fusion genes as therapeutic targets for RNA interference (RNAi). In addition, the design of biomimetic nanoparticles which are capable of responding to the physiological environment of leukaemia and their potential to advance RNAi therapeutics to the clinic will be critically evaluated.     

Combination of attenuated Salmonella carrying PD-1 siRNA with nifuroxazide for colon cancer therapy

Colon cancer is a member of malignant tumors in the digestive system. Traditional treatment strategies are ineffective and improving the treatment of colon cancer is an urgent need. Targeting programmed cell death-1 (PD-1) by monoclonal antibodies has shown some therapeutic effectiveness and has advantages. Additionally, the Stat3 inhibitor nifuroxazide was employed to promote the antitumor activity. Here, we hypothesized that combining nifuroxazide with PD-1 small interfering RNA carried by attenuated Salmonella would exert a synergistic antitumor effect on colon cancer. Indeed, treatment with this combination effectively inhibited the development of colon cancer in mice and improved the survival rate. These two novel anticancer agents worked synergistically to elicit potent antitumor immunity and achieve improved therapeutic efficacy. The underlying mechanisms are mainly involved with immune regulation and cell apoptosis. This study provides a previous framework for combining this Stat3 inhibitor with RNAi designed to block immune checkpoint signaling for cancer therapy.     

RNA interference: a tool for querying nervous system function and an emerging therapy

RNA interference (RNAi), a mediator of gene silencing, has swiftly become one of the most exciting and applicable biological discoveries. There has been rapid progress in identifying RNAi pathway components and elucidating the mechanisms of microRNA (miRNA) biogenesis and gene suppression. As a result, RNAi technologies have been successfully employed in a variety of systems as biological tools, and studies are underway to test the therapeutic utility of RNAi. In the span of several years, significant advances in the delivery of inhibitory RNAs in the nervous system have been made. We have glimpses into how endogenous miRNAs interface with neuronal development and function; in addition, RNAi has shown therapeutic efficacy in several mouse models of human neurological conditions. In this review, we summarize the current state-of-the-art of RNAi and its utility to neuroscientists.     

胚胎干细胞研究的新工具:RNA干扰

胚胎干细胞研究是20世纪90年代以来在生物医学领域中最引人注目的热点之一,而新近发展起来的RNA干扰技术,能快速有效地沉默基因表达,将成为胚胎干细胞生物学研究的得力工具。现对RNA干扰的作用机制,以及RNA干扰应用于胚胎干细胞研究的方法与RNA干扰在胚胎干细胞研究领域的进展作一综述,以期为今后这方面的研究提供参考。     

miRNA与siRNA胃癌相关研究的现状及进展

RNA干扰是表观遗传学的研究热点,它参与基因复制后表达调控,并与肿瘤发生密切相关。近年对RNA干扰研究较多的是微小RNA和小干扰RNA。文章概述了微小RNA和小干扰RNA的基本理论,并综述它们在胃癌研究中的现状及进展。认为RNA干扰分析和应用是研究胃癌相关基因功能及作用机制的有效方法,并将对胃癌的诊治产生巨大影响。     

昆虫RNAi通路及其核心元件的研究综述

RNAi作为分子生物学的一种重要技术,在昆虫基因功能和功能基因组研究中得到广泛应用,同时,有关昆虫RNAi的机制也受到了大家的关注。近年来的研究结果表明,昆虫RNAi的通路与其他动物相同,根据引起基因沉默的RNA分子的类型,可以分为siRNA、miRNA和piRNA 3种不同的通路。昆虫RNAi通路中的核心元件包括了:(1)行使切割作用的RNaseⅢ家族成员Drosha和Dicer;(2)用来降解目的 mRNA的Argonaute蛋白;(3)dsRNA结合蛋白Pasha、R2D2和Loquacious。了解昆虫RNAi的通路及其核心元件,有助于我们更好地理解昆虫RNAi的分子机制和改进实现RNAi的方法,对促进昆虫RNAi技术的研究及其在害虫防控中的应用具有指导意义。